Yingnan Liu1, Yueyi Zhang2, Yumei Wei3,4, Huixia Yang5,6. 1. Department of Obstetrics and Gynecology, Peking University First Hospital, Peking University, No. 1, Xi 'anmen Street, Xicheng, Beijing, China. 2. Department of Internal Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 3. Department of Obstetrics and Gynecology, Peking University First Hospital, Peking University, No. 1, Xi 'anmen Street, Xicheng, Beijing, China. weiyumei1982@126.com. 4. Beijing Key Laboratory of Maternal-Fetal Medicine of Gestational Diabetes Mellitus, Beijing, China. weiyumei1982@126.com. 5. Department of Obstetrics and Gynecology, Peking University First Hospital, Peking University, No. 1, Xi 'anmen Street, Xicheng, Beijing, China. yanghuixia@bjmu.edu.cn. 6. Beijing Key Laboratory of Maternal-Fetal Medicine of Gestational Diabetes Mellitus, Beijing, China. yanghuixia@bjmu.edu.cn.
Abstract
BACKGROUND: Hydroxychloroquine (HCQ) is the primary medication in the treatment of pregnancy with systemic lupus erythematosus (SLE) for its efficacy and safety. However, the effect of HCQ on preeclampsia prevention remains controversial. OBJECTIVE: This study aimed to investigate whether HCQ has an effect on preeclampsia prevention and other pregnancy outcomes among lupus pregnancy. METHODS: We conducted a retrospective cohort study of 119 pregnant women with SLE. After the propensity score matching of baseline characteristics, the population was divided into the HCQ treatment group and HCQ nontreatment group. Then, we compared the preeclampsia and other pregnancy outcomes between HCQ treatment and nontreatment groups. Furthermore, we combined our data and previous studies for a meta-analysis. RESULTS: In our data, HCQ did not increase the risk of premature rupture of membranes, bleeding during pregnancy, preeclampsia, intrauterine distress, gestational age at delivery, preterm birth, and postpartum hemorrhage. There was no significant association between HCQ treatment and preeclampsia prevention. Besides, the meta-analysis showed a similar result that HCQ did not significantly decrease the rate of preeclampsia (RR = 0.61, 95%CI = 0.34-1.11). CONCLUSION: This study found that HCQ treatment was safe, but did not significantly reduce preeclampsia among lupus pregnancies.
BACKGROUND:Hydroxychloroquine (HCQ) is the primary medication in the treatment of pregnancy with systemic lupus erythematosus (SLE) for its efficacy and safety. However, the effect of HCQ on preeclampsia prevention remains controversial. OBJECTIVE: This study aimed to investigate whether HCQ has an effect on preeclampsia prevention and other pregnancy outcomes among lupus pregnancy. METHODS: We conducted a retrospective cohort study of 119 pregnant women with SLE. After the propensity score matching of baseline characteristics, the population was divided into the HCQ treatment group and HCQ nontreatment group. Then, we compared the preeclampsia and other pregnancy outcomes between HCQ treatment and nontreatment groups. Furthermore, we combined our data and previous studies for a meta-analysis. RESULTS: In our data, HCQ did not increase the risk of premature rupture of membranes, bleeding during pregnancy, preeclampsia, intrauterine distress, gestational age at delivery, preterm birth, and postpartum hemorrhage. There was no significant association between HCQ treatment and preeclampsia prevention. Besides, the meta-analysis showed a similar result that HCQ did not significantly decrease the rate of preeclampsia (RR = 0.61, 95%CI = 0.34-1.11). CONCLUSION: This study found that HCQ treatment was safe, but did not significantly reduce preeclampsia among lupus pregnancies.